FDA approves pozelimab-bbfg as first CHAPLE disease treatment for children, adults
August 18th 2023Regeneron states all 10 patients achieved normalization of serum albumin and serum IgG concentrations by week 12 in a phase 2/3 trial that investigated the safety and efficacy of pozelimab-bbfg. These concentrations were maintained through 72 weeks.
Study: Children exposed to COVID-19 pandemic behind 4 months in development at age 5
August 18th 2023Children followed up with at 5 years of age that were exposed to the COVID-19 pandemic were 4.39 months behind in overall childhood development, whereas children followed up with at 3 years of age demonstrated positive associations.
FDA approves palovarotene capsules to treat fibrodysplasia ossificans progressiva
August 17th 2023Palovarotene is now the first and only treatment for the ultra-rare bone disease fibrodysplasia ossificans progressive (FOP), which impacts approximately 400 people in the United States and 900 globally.
Potential links between neurological, cognitive conditions and gut microbiomes of children
August 17th 2023Watch as Rob Knight, PhD, Wolfe Endowed Chair in Microbiome Science at Rady Children's Hospital-San Diego, professor of pediatrics, UCSD, talks the gut microbiome and the potential associations with cognitive and neurological conditions in children, and why the topic is gaining interest and momentum.
Rotavirus-associated hospitalizations linked to subsequent autoimmune diseases in children
August 16th 2023Investigators concluded that clinicians should be aware, for individuals with a prior rotavirus-associated hospitalization, of an elevated susceptibility to autoimmune disease in these patients.
AAP recommends all infants receive nirsevimab to fight RSV
August 15th 2023The recommendation from the American Academy of Pediatrics (AAP) follows the unanimous recommendation by the CDC advisory group for routine use of nirsevimab in newborns and infants younger than 8 months born into or entering their first RSV season.
Chikungunya vaccine effective in adolescents after phase 3 trial
August 14th 2023Basis for a Biologics License Application submission to the FDA is being built for PXVX0317, following topline results demonstrated in a pair of phase 3 trials, including 1 trial featuring adolescents and adults aged 12 to 64 years.
Hybrid, AI stethoscope effective for detecting cardiac and respiratory disease
August 14th 2023Study authors stated that several past studies have put focus on training an independent model separately for lung or heart sound diagnosis but note that having a model that can “simultaneously detect abnormal lung and heart sounds,” is essential.
Lower IQ scores associated with diabetic ketoacidosis in young type 1 diabetes patients
August 11th 2023Results of the randomized, multi-site study demonstrated the importance of early diabetes detection, as a single episode of diabetic ketoacidosis (DKA) in young children with type 1 diabetes was associated with lower IQ scores soon after exposure.
FDA issues complete response letter to remestemcel-L for graft-versus-host disease treatment
August 10th 2023The resubmission, which included new long-term follow-up data and a post-hoc propensity match study, was issued a complete response letter by the federal agency, which requires “more data to support marketing approval,” according to a press release from Mesoblast Limited.
What is new regarding pediatric orthopedic surgery?
August 9th 2023Jeanne Franzone, MD, orthopedic surgeon, surgical director, Osteogenesis Imperfecta Clinic, co-director, Prosthesis Clinic, Nemours Children’s Health, Delaware Valley, discusses recent technology, recommendations, and interactions with general health care providers in this Contemporary Pediatrics® interview.
Does asthma predispose higher risk of severe COVID-19?
August 7th 2023In this Contemporary Pediatrics® interview, Samir Gautam, MD, (Pulmonary, Critical Care and Sleep Medicine), Yale School of Medicine, senior author of a recently published study in the Journal of Allergy and Clinical Immunology: In Practice, reviews key findings of the study and explains how they relate to the pediatric population. Watch the full interview below.
Early peanut introduction without routine testing seems safe for all children
August 4th 2023The authors noted that there is evidence that recommending early introduction of peanut without prior testing is safe and effective in increasing early peanut introduction to infants, even those at high risk.
Nirsevimab-alip unanimously recommended by CDC advisory group to prevent RSV
August 3rd 2023The ACIP voted in unanimous fashion, 10 to 0, to recommend routine use of nirsevimab-alip for newborns and infants younger than 8 months, born during or entering the first RSV season according to a press release from Sanofi.